Axcan Pharmaceuticals

AXP-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about AXP-T

Signal
Opinion
Expert
TOP PICK
TOP PICK
April 14, 2005
Part pharmaceutical and part drug development. Very profitable. Strong balance sheet and lots of cash flow. Generates about US$1.50 free cash flow every year. In a very stable gastro-intestinal market. They're also in-licence some drugs which gives them some pretty good upside. Trading at about US$14 with $1 a share free cash on the balance sheet.
Part pharmaceutical and part drug development. Very profitable. Strong balance sheet and lots of cash flow. Generates about US$1.50 free cash flow every year. In a very stable gastro-intestinal market. They're also in-licence some drugs which gives them some pretty good upside. Trading at about US$14 with $1 a share free cash on the balance sheet.
Chris Fernyc
Portfolio Manager, Bissett Investment
Price
$18.600
Owned
Yes
TOP PICK
TOP PICK
November 24, 2004
A very focused (gastro intestinal) pharmaceutical company and as a result, it is very profitable. You pretty well get a free call option on a potentially block-buster drug called Itax. Huge market in North America.
A very focused (gastro intestinal) pharmaceutical company and as a result, it is very profitable. You pretty well get a free call option on a potentially block-buster drug called Itax. Huge market in North America.
Fred Pynn
Portfolio Manager, Bissett Investment Management
Price
$20.980
Owned
Yes
TOP PICK
TOP PICK
November 9, 2004
Last news was that R&D spending would be higher than the street anticipated. Launching a product that could be a $200 million product.
Last news was that R&D spending would be higher than the street anticipated. Launching a product that could be a $200 million product.
Danny Tomka
Portfolio Manager, MFC Global Investment Management
Price
$19.500
Owned
Yes
BUY
BUY
November 11, 2003
Has a very good ROE. Efficient balance sheet structure. Continuing to grow their earnings. Valuation is reasonable.
Has a very good ROE. Efficient balance sheet structure. Continuing to grow their earnings. Valuation is reasonable.
Peter Arender, CFA
Unknown, Unknown
Price
$17.400
Owned
Unknown
TOP PICK
TOP PICK
November 3, 2003
The entire US financial sector is attractive. Their brokerage sector is growing rapidly. Expects travel business will pick up.
The entire US financial sector is attractive. Their brokerage sector is growing rapidly. Expects travel business will pick up.
John Sinkins, CFA
Senior Portfolio Manager, Sentry Select Capital Corp
Price
$47.230
Owned
Yes
DON'T BUY
DON'T BUY
May 20, 2003
Its OK earnings wise. They are trying to make a hostile take over which looks expensive. Core business is OK.
Its OK earnings wise. They are trying to make a hostile take over which looks expensive. Core business is OK.
Glenn Paradis, BA, CFA
Vice President & Sr Portfolio Manager, Equities, Aegon Capital Management Inc.
Price
$16.930
Owned
Unknown
BUY
BUY
January 20, 2003
A good long term hold. They focus on their earnings. Well managed.
A good long term hold. They focus on their earnings. Well managed.
Pierre Bernard
Vice President of Canadian Equities, Industrial Alliance Fund Management
Price
$17.850
Owned
Unknown
DON'T BUY
DON'T BUY
January 31, 2002
Had a nice run. May be a bit high now.
Had a nice run. May be a bit high now.
Malvin Spooner
Chairman and Chief Executive Officer, Mavrix Fund Management
Price
$21.500
Owned
Unknown
STRONG BUY
STRONG BUY
December 11, 2000
Products selling very well. Sales force based in US
Products selling very well. Sales force based in US
Ed Ho
Portfolio Manager, Dynamic Mutual Funds
Price
$14.950
Owned
Unknown
Showing 1 to 9 of 9 entries
  • «
  • 1
  • »